timothy sykes logo
RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype Thumbnail
G Google News

RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype

JACK KELLOGG•UPDATED OCT. 19, 2026, 4:47 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Recursion Pharmaceuticals Inc. stocks have been trading up by 4.26 percent following optimism over its latest AI-driven drug discovery advances.

Key Takeaways For RXRX Traders

  • Strong REC-4881 TUPELO data in familial adenomatous polyposis show meaningful polyp reductions, durable benefit after stopping therapy, and safety in line with MEK1/2 inhibition.
  • Early REC-1245 Phase 1 oncology data delivered three partial responses and a 91.7% disease control rate, giving Recursion Pharmaceuticals a credible solid-tumor shot on goal.
  • Sanofi exercised its option on the first AI-discovered inflammatory candidate from the RXRX collaboration, triggering a $10M milestone and leaving over $300M in potential milestones plus royalties.
  • An oversubscribed $200M follow-on at $3.25 per share extends Recursion’s cash runway into 2029, though it dilutes existing holders.
  • Cathie Wood’s ARK Investment Management has been aggressively buying RXRX while Morgan Stanley nudged its price target to $5.90 with an Equal Weight rating.

Candlestick Chart

Live Update At 16:46:52 EDT: On Monday, October 19, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 4.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been on a wild ride in October. The daily chart shows Recursion Pharmaceuticals swinging from a close near $4.78 on 2026/10/05 to $3.61 on 2026/10/19, with big spikes and sharp fades in between. That 15.4% surge to $4.32 on 2026/10/15 stands out as a classic momentum burst tied to the news cluster.

The intraday tape on the latest session tells a different story. RXRX opened active but then settled into a tight range between roughly $3.58 and $3.67 for most of the day. That kind of low-range churn after a selloff often signals traders taking a breather, absorbing supply around new support.

Fundamentally, Recursion Pharmaceuticals is still early-stage biotech. Revenue is just $74.3M, yet the price-to-sales ratio sits near 43x, which screams “story stock.” Margins are deeply negative, with EBITDA at about -$112.5M last quarter and free cash flow around -$107.9M. On the plus side, RXRX holds $545.7M in cash and short-term investments, a current ratio near 5, and very low debt.

More Breaking News

For traders, that mix means heavy burn but a long runway, especially after the fresh $200M raise. RXRX is priced on future execution, not current earnings.

Why Traders Are Watching RXRX Right Now

RXRX is suddenly back on a lot of radar screens because the story just lined up on three fronts: clinical, capital, and credibility.

On the clinical side, Recursion Pharmaceuticals dropped two important data sets. The Phase 1b/2 TUPELO trial for REC-4881 in familial adenomatous polyposis showed substantial reductions in GI polyp burden and, more impressively, sustained benefit even after stopping treatment. For a hereditary condition tied to high cancer risk, that kind of durable effect matters. The safety profile looked consistent with MEK1/2 inhibition, which helps de-risk the asset. Traders know mid-stage success in a clear niche can support long-term optionality, even if commercial revenue is years away.

Then there is REC-1245, RXRX’s “molecular glue” targeting RBM39. Early Phase 1 data showed three partial responses and a 91.7% disease control rate at doses ≥45 mg QD in heavily pretreated solid tumor patients, with a clean enough safety profile to justify dose expansion in endometrial cancer. That tells the tape Recursion Pharmaceuticals is not just an AI buzzword; it is generating real oncology signals.

The second leg of the story is Sanofi. The pharma giant officially optioned the first dual-target immunology small-molecule candidate from its multi-program collaboration with RXRX, triggering a $10M milestone and bringing total collaboration payments to $144M. Recursion remains eligible for over $300M more in milestones plus low double-digit royalties if things progress. That is external validation of the platform from serious money.

Finally, RXRX raised $200M in an oversubscribed follow-on at $3.25, backed by high-quality healthcare funds. Yes, that dilutes. But it also pushes the cash runway into 2029 and takes near-term financing fear off the table. Layer on aggressive buying from Cathie Wood’s ARK—multiple blocks of 1.5M, 1.9M, and 4.2M shares—and you get a name where institutional money is leaning in just as the news flow turns.

Conclusion

For active traders, RXRX is the kind of volatile biotech that rewards preparation. Recursion Pharmaceuticals now has early wins in FAP with REC-4881, promising molecular glue data with REC-1245, a validated AI-driven tie-up with Sanofi, and a balance sheet reinforced by an oversubscribed $200M equity raise. That combination explains the recent 15%+ spike and the choppy pullback that followed.

At the same time, the numbers remind everyone what this is: a high-burn, high-upside platform bet. Margins are deeply negative, and RXRX trades on future milestones, trial readouts, and partnership progress, not on current profits. The repeated ARK Investment buying and Morgan Stanley’s target bump to $5.90 add sentiment fuel, but they do not remove biotech risk or the overhang from dilution.

This is where trading discipline matters. RXRX can trend hard when news and momentum align, then unwind just as quickly when the hype cools. As Tim Sykes loves to remind traders, “Patterns repeat, but you still need to cut losses quickly because no pattern works 100% of the time.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. With Recursion Pharmaceuticals, the pattern right now is clear: strengthening fundamentals, rising institutional interest, and a chart that will reward those who respect both the upside and the downside. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”